Anti-Human TRAIL-R2 Recombinant Antibody (Lexatumumab) (CAT#: TAB-195)

Recombinant monoclonal antibody to TRAIL-R2. Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA

Figure 1 Cleaved caspase 8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.

Figure 1 Cleaved caspase 8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.

Immunoprecipitation assays of mapatumumab (Mapa) or lexatumumab (Lexa) were performed in LP1, MDN, NCI-H929 cells. Cells (20 x 106) were incubated with or without (control) 10ug/ml of mapatumumab (45min) or lexatumumab (90 min) at 37°C in RPMI1640 containing 5% FCS. For NCIH929, cells were pretreated 2h with 2.5uM nutlin3a (N) before addition of lexatumumab. The lysates were immunoprecipitated with a mix of proteins A and G (2 mg of lysate proteins were immunoprecipitated in each assay). For untreated cells, IP was performed after addition of mapatumumab or lexatumumab to the lysates. The immunoprecipitates were analyzed for the presence of the indicated proteins by immunoblot analysis. Input: lysates of untreated or treated cells, Ct IP: immunoprecipitation of control lysates (untreated cells), IP: immunoprecipitation of lysates obtained from cells treated with mapatumumab or lexatumumab. * indicates heavy chain of mapatumumab or lexatumumab.

Surget, S., Chiron, D., Gomez-Bougie, P., Descamps, G., Ménoret, E., Bataille, R., ... & Pellat-Deceunynck, C. (2012). Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer research, canres-0487.

Figure 2 TGFβ1 inhibits apoptotic signaling of TRAIL-R1.

Figure 2 TGFβ1 inhibits apoptotic signaling of TRAIL-R1.

Cells were treated for 24 h with Mapatumumab (10μg/ml, Mapa), Lexatumumab (10μg/ml, Lexa), with or without pre-incubation with TGFβ1 (10 ng/ml for 72 h). Cell death was determined by PI-staining followed byflow cytometric analysis. (A) or by measurements of ATP content using the commercial CellTiter-Glo Luminescent Cell Viability Assay (B). Induction ratio shown in (A) (Mapa or Lexa treatment/respective control) is indicated below the histograms as fold of induction. Data depicted in A) and B) are shown as mean ± SEM of three independent experiments. *pb0.05, n.s. non-significant. (C) Cells were treated for 24 h with Mapa (10μg/ml), Lexa (10μg/ml), or with TRAIL (50 ng/ml) with or without pre-incubation with TGFβ1 (10 ng/ml for 72 h). Analysis of the apoptotic signaling cascade was performed on whole cell lysates by Western blot using antibodies against caspase 8, Bid and caspase 3. For the control of the gel loading,β-actin levels were determined in parallel.

Radke, D. I., Ungefroren, H., Helm, O., Voigt, S., Alp, G., Braun, H., ... & Kalthoff, H. (2016). Negative control of TRAIL-R1 signaling by transforming growth factor β1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1. Cellular signalling, 28(11), 1652-1662.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Human
  • Derivation
  • Human
  • Type
  • IgG1 - lambda
  • Specificity
  • Tested positive against native human antigen.
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, ICC
  • CAS
  • 845816-02-6
  • Generic Name
  • Lexatumumab
  • UNII
  • 967Q0SJD77
  • MW
  • 143.6 kDa
  • Related Disease
  • Cancers

Product Property

  • Purity
  • >95.0% as determined by analysis by SDS-PAGE.
  • Storage
  • Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

Applications

  • Application Notes
  • The TNFRSF10B antibody has been reported in applications of IP, WB.

Target

  • Alternative Names
  • Lexatumumab;845816-02-6;ETR2-ST01;HGS-ETR2;HGS1018;ETR2-ST01;TNFRSF10B;tumor necrosis factor receptor superfamily, member 10b;tumor necrosis factor receptor superfamily member 10B;CD262;DR5;KILLER;TRAIL R2;TRICK2A;TRICKB;Fas-like protein;death receptor 5;

Related Resources

  • Biosimilar Overview
Please refer to Lexatumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Lexatumumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Lexatumumab"

Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Lexatumumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant monoclonal antibody to TRAIL-R2. Lexatumumab (also known as ETR2-ST01) is an experimental agonistic human monoclonal antibody against TRAIL-R2 (DR5, APO-2) undergoing clinical trials for the treatment of cancer.

See other products for "TNFRSF10B"

Human Antibody

Rat Antibody

CAT Product Name Application Type
TAB-625CL Human Anti-TNFRSF10B Recombinant Antibody (TAB-625CL) ELISA Single Domain Antibody

Agonistic Antibody

CAT Product Name Application Type
MOB-104LC Human Anti-TNFRSF10B Recombinant Antibody (MOB-104LC) FuncS Chimeric (mouse/human) IgG1, κ

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-196 Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Tigatuzumab), ADCC Enhanced IF, IP, Neut, FuncS, ELISA, FC ADCC enhanced antibody
AFC-TAB-203 Afuco™ Anti-TNFRSF10B Recombinant Antibody (AFC-TAB-203), ADCC Enhanced ELISA, IP, FC, FuncS, Neut, IF Human IgG1, κ
AFC-TAB-180 Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Drozitumab), ADCC Enhanced FuncS, IF, Neut, ELISA, FC, IP ADCC enhanced antibody
AFC-TAB-195 Afuco™ Anti-TNFRSF10B ADCC Recombinant Antibody (Lexatumumab), ADCC Enhanced ELISA, IP, FC, FuncS, Neut, IF ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-195. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare